In 2024, Teva Pharmaceutical Industries Limited.. completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Teva Pharmaceutical Industries Limited.. has also provided a category-level breakdown for 13 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 243,603a | 242,056a | 253,306a | |
Total Scope 2 | ||||
Market-Based | 218,504a | 239,069a | 237,815a | |
Location-Based | 337,970a | 349,260a | N/A | |
Total Scope 3 | 4,066,116a | 4,320,235a | 4,335,503a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 14.7246a | 15.2765a | 16.9719a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Teva Pharmaceutical Industries Limited.. amounted to 581,573 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Teva Pharmaceutical Industries Limited.. decreased by 1.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Teva Pharmaceutical Industries Limited.. were 243,603 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Teva Pharmaceutical Industries Limited..'s Scope 1 emissions have decreased by 18.57%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Teva Pharmaceutical Industries Limited..'s Scope 1 emissions remained relatively stable, indicating that Teva Pharmaceutical Industries Limited..'s emissions have plateaued with no significant change in its operational footprint.a
In 2024, Teva Pharmaceutical Industries Limited.. reported Scope 2 greenhouse gas (GHG) emissions of 218,504 tCO₂e using the market-based method and 337,970 tCO₂e using the location-based method.a
Compared to the previous year (2023), Teva Pharmaceutical Industries Limited..'s Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Teva Pharmaceutical Industries Limited..'s emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Teva Pharmaceutical Industries Limited.. reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Teva Pharmaceutical Industries Limited.. reported 4,066,116 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Teva Pharmaceutical Industries Limited.. includes a breakdown across 13 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Teva Pharmaceutical Industries Limited.. reported total Scope 3 emissions of 4,066,116 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 68.62% of these emissions originated from upstream activities such as purchased goods and capital goods, while 31.38% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Teva Pharmaceutical Industries Limited..'s Scope 3 emissions remained relatively stable, indicating that Teva Pharmaceutical Industries Limited..'s emissions have plateaued with no significant change in its value chain footprint.a
In 2024, Teva Pharmaceutical Industries Limited.. reported emissions for 13 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Teva Pharmaceutical Industries Limited..'s Scope 3 emissions were:a
In 2024, Teva Pharmaceutical Industries Limited.. reported Scope 1 greenhouse gas (GHG) emissions of 243,603 tCO₂e and total revenues of USD 16,544 millions. This translates into an emissions intensity of 14.72 tCO₂e per millions USD.a
In 2024, Teva Pharmaceutical Industries Limited.. reported a Scope 1 emissions intensity of 14.72 tCO₂e per millions USD. Compared to the peer group median of 10.33, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Teva Pharmaceutical Industries Limited.. ranked 15 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Teva Pharmaceutical Industries Limited.. is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Teva Pharmaceutical Industries Limited.. reported a total carbon footprint of 4,647,689 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.37% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Teva Pharmaceutical Industries Limited..'s total carbon footprint was Scope 3 emissions, accounting for 87.49% of the company's total carbon footprint, followed by Scope 2 emissions at 7.27%.a